Cel Europe's consumers are increasingly requesting products that are organically and sustainably produced. At the same time, Europe has been lacking incentives to develop and bring to markets new marine products, without increasing pressure on natural resources.The innovation in question; a natural, sustainably produced medicine based on marine oils, addresses these challenges. It is based on the discovery that omega-3 oils have proven to have laxative effects. It offers parents and pediatricians a pain-free alternative to other pharmaceutical products, in a market where no new products have been introduced for decades. The innovation also paves the way for the full utilization of marine products, demonstrating that by-products can be of high value for other industries, including the pharmaceutical sector.The aim of the applicant is to develop this innovation all the way towards a market-ready, licensed pharmaceutical product. The pharmaceutical industry is one of the largest industries in the world in regards to revenues. Over 100 million people worldwide, suffer from constipation. The active ingredient of the innovation product would be a new and a unique addition to this growing market.The applicant seeks support to be able to obtain a solid analysis of the market potential for the innovation. If successfully brought to markets, it will reach the milestone of being the first non-generic, registered drug, tested in clinical trials in humans that was discovered, developed and produced in one of Europe's most peripheral corners, Iceland. Dziedzina nauki medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health scienceshealth sciencespublic healthepidemiologynatural sciencesbiological sciencesbiochemistrybiomoleculeslipids Program(-y) H2020-EU.3.2. - SOCIETAL CHALLENGES - Food security, sustainable agriculture and forestry, marine, maritime and inland water research, and the bioeconomy Main Programme H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Temat(-y) BG-12-2014-1 - Supporting SMEs efforts for the development - deployment and market replication of innovative solutions for blue growth Zaproszenie do składania wniosków H2020-SMEInst-2014-2015 Zobacz inne projekty w ramach tego zaproszenia Szczegółowe działanie H2020-SMEINST-1-2014 System finansowania SME-1 - SME instrument phase 1 Koordynator LIPID PHARMACEUTICALS EHF Wkład UE netto € 50 000,00 Adres LAEKJARGOTU 12 101 REYKJAVIK Islandia Zobacz na mapie MŚP Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant. Tak Region Ísland Ísland Höfuðborgarsvæði Rodzaj działalności Private for-profit entities (excluding Higher or Secondary Education Establishments) Linki Kontakt z organizacją Opens in new window Uczestnictwo w unijnych programach w zakresie badań i innowacji Opens in new window sieć współpracy HORIZON Opens in new window Koszt całkowity € 71 429,00